<DOC>
	<DOCNO>NCT02143622</DOCNO>
	<brief_summary>To establish whether LJM716 combination cetuximab safe beneficial effect patient platinum-pretreated recurrent/metastatic head neck squamous cell carcinoma .</brief_summary>
	<brief_title>Study Efficacy Safety LJM716 Cetuximab Head Neck Squamous Cell Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Most recent regimen contain platinum cetuximab ( Phase II , group B ) . ECOG Performance Status ( PS ) ≤ 2 . Recovery AEs previous anticancer therapy , baseline CTCAE Grade ≤ 1 , except alopecia . Measurable disease determine RECIST v1.1 . Previous antiHER3 antibody treatment . Symptomatic brain metastasis . Prior systemic anticancer treatment , within period time short cycle length use treatment prior start study treatment . Prior anaphylactic severe infusion reaction human immunoglobulin antibody formulation . Inadequate end organ function . Ongoing diarrhea CTCAE Grade ≥ 2 . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Head neck cancer</keyword>
</DOC>